Clinical trial · no report yet · Phase 2
SBRT-AMICO
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
- NCT05915442 ↗
- Recruiting
- Catherine Spina
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Phase II Single Arm Study Testing SBRT, Adenosine Signaling Modulation (AB680, AB928), and Immune Checkpoint Inhibition (AB122) for Men With Hormone Sensitive Oligometastatic Prostate Cancer
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Oligometastatic Prostate Cancer
- Interventions
- Quemliclustat; Etrumadenant; Zimberelimab; Stereotactic Body Radiation Therapy
- Arms
- Treatment with quemliclustatm, etrumadenant, zimberelimab and SBRT · Experimental
- Enrollment
- 23 (estimated)
- Primary outcomes
- Biochemical recurrence-free survival at 12-months
- Sponsor
- Catherine Spina with Arcus Biosciences, Inc.
- Start
- Jul 1, 2023
- Primary completion
- Dec 1, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05915442 · updated May 20, 2025